abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

Diese Seite ist nicht auf Deutsch verfügbar und wird angezeigt auf English

Unternehmensantwort

9 Jan 2015

Autor:
Gilead Sciences

Gilead Sciences' Response

...Gilead Sciences is working to help ensure access to its chronic hepatitis C medicines for all patients who can benefit from them. The company is... working with national governments to provide its branded medicines...As part of these efforts Gilead and its partners are designing measures to ensure that these high value curative medicines are not diverted...

Read full response here

Zeitleiste